Ouro Medicines, a San Francisco, CA-based biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, launched with $120m in Series A funding.
The Series A was co-led by TPG Life Sciences Innovations, NEA, and Norwest Venture Partners, with participation from Monograph Capital, GSK, UPMC Enterprises, Boyu/Zoo Capital, LongRiver Investments, and other unnamed investors.
Founded by Monograph Capital in partnership with GSK plc., Ouro Medicines is a biotechnology company dedicated to developing immune reset therapeutics for people living with chronic immune-mediated diseases. Its most advanced product candidate is OM336, a BCMA-directed, bispecific T cell engager recently licensed from Keymed Biosciences (2162.HK). BCMA is highly expressed across several B cell subtypes that play a role in driving multiple indications where high specificity and potency are needed to achieve near-complete B cell depletion.
Keymed Biosciences is currently studying OM336 (CM336) in an ongoing Phase 2 expansion study in multiple myeloma in China. Ouro holds exclusive rights outside of Greater China and intends to start its first Phase 1 study in 2025. Examples of B cell mediated diseases include systemic lupus erythematosus, scleroderma, rheumatoid arthritis, Sjögren’s, and myositis. Supportive proof of concept data has been generated from the off-label use of BCMA-directed TCEs in these indications.
Behind its lead program, the company intends to advance a broad set of discovery programs targeting additional dimensions of B cell biology. These programs probe unique subsets of B cells compared to existing therapies in the clinic. Additionally, the company’s protein engineering expertise is being applied to next-generation versions of novel TCEs to continue to drive innovative treatments for chronic immune-mediated diseases.
Ouro has assembled a leadership team with expertise in a range of relevant diseases and modalities, including:
- Jaideep Dudani, PhD, Chief Executive Officer.
- Neely Mozaffarian, MD, PhD, Chief Medical Officer.
- Christina Carlson, JD, Chief Administrative Officer.
- Kevin P. Baker, PhD, Chief Development Officer.
Ouro’s Board of Directors includes Shinichiro Fuse, PhD (TPG), Matt McAviney, MD (NEA), Brian Matesic, MD (Norwest), Tim Funnell, DPhil (Monograph), and Bo Chen, PhD (Keymed).
Supporting the Ouro leadership team are several deeply experienced clinical advisors, including John Davis, MD, MPH, President, Norte Health Consulting and former scientific advisory board member of HI-Bio; Matthew Baker, MD, MS, Clinical Chief in the Division of Immunology and Rheumatology at Stanford University and the Co-Director of the Stanford Multidisciplinary Sarcoidosis Program; and Stanford Peng, MD, PhD, most recently President and Head of Research & Development at Alpine Immune Sciences.
FinSMEs
10/01/2025